received at the laboratory). Compared with direct immunofluorescence, near patient testing showed a sensitivity of 79% (95% confidence interval 67.3% to 88.5%), a specificity of 97% (82.8% to 99.9%), a positive predictive value of 98% (89.6% to 99.9%), and a negative predictive value of 70% (53.9% to 82.8%).
Infection with hepatitis C and hepatitis B viruses is common among injecting drug users. [1] [2] [3] [4] In a sample of blood donors only 0.01% were positive for antibodies to hepatitis C virus, 5 whereas 59% of injecting drug users in East Anglia were positive, with 22% also positive for hepatitis B virus. 2 Rhodes et al reported that about half (58% in 1992 and 50% in 1993) of those whose salivary specimens contained antibodies to hepatitis B virus were unaware of their infection. 4 Although drug users are generally aware of the risks of infection, their awareness of their own status is uncertain. We tested opiate addicts receiving methadone maintenance treatment for markers of hepatitis B and hepatitis C infection and compared the results with their beliefs about their viral status.
Subjects, methods, and results
We collected data on 106 injecting opiate addicts attending a methadone maintenance clinic in London. Sufficient blood was obtained for 90 hepatitis C virus tests and for 84 hepatitis B virus tests (when blood was insufficient, priority was given to hepatitis C). We present data for the 90 addicts from whom blood was obtained.
The participants' mean age was 36 years (range 21-54), and 69 were men. They had attended the clinic for an average of 2.4 years and received a mean methadone dose of 72 mg (range 15-150 mg). Their mean age at first opiate injection was 21, and the mean duration of injecting was 15 years. Fifty nine had used a syringe after someone else, and 68 had shared injecting paraphernalia.
Seventy seven were positive for hepatitis C virus, and 46 were positive for hepatitis B virus. Of the 79 who reported having previously been tested for hepatitis C virus, 58 thought they were positive, 16 thought they were negative (of whom half were wrong), and five were uncertain. Of the 70 addicts previously tested for hepatitis C virus whom we found to be positive, 12 did not know or were wrong about their status (see table) . Of the 41 previously tested for hepatitis B virus whom we found to be positive, 16 thought themselves to be negative.
Of the 11 addicts never previously tested for hepatitis C virus, four were correct in their self assessment (one positive, three negative), four incorrectly thought they were negative, and three did not know. Of the 22 addicts not previously tested for hepatitis B virus, six were correct in their self assessment (all negative), while three mistakenly believed they were positive and one negative, and 12 could not report their viral status (five positive, seven negative). Subjects never previously tested for hepatitis B virus were less likely to be seropositive (5/22 v 41/62; 2 = 10.66, df = 1, P < 0.005). A similar pattern was seen for hepatitis C virus positivity (7/11 v 70/79; 2 = 3.06, df = 1, P < 0.10). Of the 33 addicts not previously tested for hepatitis B or hepatitis C virus, only 10 accurately perceived their combined status.
Discussion
Our finding of 86% seropositivity for hepatitis C virus is consistent with the 67% found among Australian injecting drug users 1 and 75% among UK addicts receiving maintenance treatment. 3 The participants' perceptions of their viral status were often inaccurate: for both hepatitis B and hepatitis C virus, they tended to believe they were negative when they were positive. If untested drug users assume they are positive and act accordingly they pose no threat to public health. If they mistakenly presume negative status, this may have serious public health consequences. Clinicians should encourage testing in all patients who are injecting drug users and use this as a catalyst for interventions. As Crofts et al point out, 1 drug treatment alone is not sufficient in reducing hepatitis seroconversion and clinicians must be more vigorous in encouraging drug users to reduce risk behaviours.
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Effect of mass media campaign to reduce socioeconomic differences in women's awareness and behaviour concerning use of folic acid: cross sectional study
In September 1995, a mass media campaign on the use of folic acid to reduce the risk of fetal neural tube defects started in the Netherlands. 1 Special emphasis was placed on reaching women in low socioeconomic categories. We describe the effect of the campaign on awareness and use of folic acid in relation to socioeconomic status.
Subjects, methods, and results
We measured the effect of the campaign by comparing two cross sectional studies-one conducted before the campaign and one conducted after the campaign. We asked pregnant women in four regions of the Netherlands attending their first or second antenatal visit to fill out a questionnaire; all did so.
We took highest fulfilled education, a recognised indicator of socioeconomic status, and merged it into three levels: low, middle, and high. We used multivariate logistic regression to calculate adjusted odds ratios for high versus low education. The methodology has been described elsewhere. 2 In both studies, 90% of the pregnancies were planned. After the campaign, 89.1% (1437/1612) of the respondents had heard about folic acid and 76.9% (1240) had heard about it before their pregnancy; the table shows how this is related to level of education. 
